EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)

IOP Injection, A Novel Superparamagnetic Iron Oxide Particle MRI Contrast Agent for the Detection of Hepatocellular Carcinoma: A Phase II Clinical Trial

Chi-Feng Chiang iD, Yuan-Hung Hsu, Wen-Yuan Hsieh, Tzu-Hsin Liao, Chih-Lung Chen, Yung-Chu Chen, Po-Chin Liang, Shian-Jy Wang

Journal of Magnetic Resonance Imaging · 2023

DOI: 10.1002/jmri.28645 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal of Magnetic Resonance Imaging, 2023. Verfasst von Chi-Feng Chiang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, National Taiwan University, Taipei, Taiwan. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Magnetite Nanoparticles. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 19 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

MRI is crucial in diagnosing hepatocellular carcinoma (HCC). Superparamagnetic iron oxide particles (SPIO) are liver‐specific contrast agents which enhance lesions in T 2 ‐weighted images. Iron oxide nano‐particle m‐PEG‐silane (IOP) Injection, a newly developed SPIO, showed promising imaging effects and good safety profile in preclinical studies and in phase I clinical trial.

Purpose

To evaluate the safety and clinical validity of IOP Injection as MRI contrast agent in diagnosing HCC. Study type Prospective. Subjects A total of 52 subjects (61.6 ± 11.05 years, 45 males/7 females) with suspected HCC. Field Strength/Sequence 1.5 T , T 1 ‐weighted in/opposed phase, T 2 *‐weighted gradient echo, T 2 ‐weighted fast spin echo, true fast imaging with steady‐state free precession. Assessment Adverse effects and clinical monitoring were recorded throughout the 5‐day study. Two independent readers (M.G.H. with 30 years of experience, S.P.K. with 26 years of experience) made the diagnosis. The diagnostic performance of IOP‐enhanced MRI was evaluated with sensitivity and positive predictive value by comparing to the pathology reports from subsequent hepatic resection. The number of lesions with various sizes and degrees of differentiation detected by IOP‐enhanced MRI was assessed. The relative change in signal intensities over time was indirectly measured from acquired images. Statistical Tests Sensitivity and positive predictive value were used to evaluate the diagnostic performance of IOP‐enhanced MRI. Prevalence‐adjusted and bias‐adjusted 𝜅 coefficient was used to assess the interreader variability.

Results

No serious adverse event related to IOP Injection was found. IOP Injection enhanced the lesion‐to‐liver contrast ratio in T 2 *‐weighted images by 50.1% ± 4.8%. IOP‐enhanced MRI detected HCC with 100% sensitivity by subject and 96% sensitivity by lesion. IOP Injection visualized subtle vascular invasion as filling defect within vessels in true fast imaging with steady‐state free precession (TrueFISP) images. Data Conclusion IOP Injection was safe and efficacious as MRI contrast agent in diagnosing HCC in a limited group of subjects. Evidence Level 2. Technical Efficacy Stage 2.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsMagnetite NanoparticlesMaleFemaleHumansContrast MediaProspective StudiesFerrosoferric OxideIronMagnetic Resonance ImagingDextransSensitivity and SpecificityFerric Compounds

Stichwörter der Autor:innen

hepatocellular carcinomaliver specific contrast agentmagnetic resonance imagingsuperparamagnetic iron oxide particles

Substanzen

Contrast MediaFerrosoferric OxideMagnetite NanoparticlesIronDextransferric oxideFerric Compounds

Autor:innen und Institutionen

  • Department of Biomedical Engineering, National Taiwan University, Taipei, Taiwan.
  • MegaPro Biomedical Co. Ltd., Zhubei City, Hsinchu County, Taiwan.
  • Department of Medical Imaging, National Taiwan University Hospital, Taipei, Taiwan.
  • Department of Medical Imaging, National Taiwan University Hospital Hsinchu Branch, Hsinchu, Taiwan.

ORCID-Profile: Chi-Feng Chiang

Zitieren

APA

Chiang, C. F., Hsu, Y. H., Hsieh, W. Y., Liao, T. H., Chen, C. L., Chen, Y. C., Liang, P. C., & Wang, S. J. (2023). IOP Injection, A Novel Superparamagnetic Iron Oxide Particle MRI Contrast Agent for the Detection of Hepatocellular Carcinoma: A Phase II Clinical Trial. Journal of Magnetic Resonance Imaging. https://doi.org/10.1002/jmri.28645

Vancouver

Chiang CF, Hsu YH, Hsieh WY, Liao TH, Chen CL, Chen YC, et al. IOP Injection, A Novel Superparamagnetic Iron Oxide Particle MRI Contrast Agent for the Detection of Hepatocellular Carcinoma: A Phase II Clinical Trial. Journal of Magnetic Resonance Imaging. 2023. doi:10.1002/jmri.28645

BibTeX
@article{Chiang2023,
  author = {Chiang, Chi-Feng and Hsu, Yuan-Hung and Hsieh, Wen-Yuan and Liao, Tzu-Hsin and Chen, Chih-Lung and Chen, Yung-Chu and Liang, Po-Chin and Wang, Shian-Jy},
  title = {IOP Injection, A Novel Superparamagnetic Iron Oxide Particle MRI Contrast Agent for the Detection of Hepatocellular Carcinoma: A Phase II Clinical Trial},
  journal = {Journal of Magnetic Resonance Imaging},
  year = {2023},
  doi = {10.1002/jmri.28645}
}
Kostenlos starten →